Your prediction
Pros and Cons of Eagle Pharmaceuticals Inc in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Eagle Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.000% | -2.778% | -5.405% | -0.943% | -2.778% | -38.235% | -57.143% |
| Corcept Therapeutics Inc. | 1.110% | 1.733% | 21.068% | 57.244% | 42.527% | 243.169% | 435.495% |
| Supernus Pharmaceuticals | -0.980% | 8.021% | -4.717% | 17.442% | -6.047% | 40.278% | 92.381% |
Comments
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) was downgraded by analysts at Piper Sandler from a "neutral" rating to an "underweight" rating.
Show more
Ratings data for EGRX provided by MarketBeat

